Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective.
Adolescent
Adult
Blood Glucose
/ analysis
Blood Glucose Self-Monitoring
/ economics
Child
Child, Preschool
Cost of Illness
Costs and Cost Analysis
Diabetes Mellitus, Type 1
/ blood
Equipment and Supplies
/ economics
Europe
/ epidemiology
Humans
Hypoglycemic Agents
/ administration & dosage
Infant
Infant, Newborn
Insulin
/ administration & dosage
Insulin Infusion Systems
/ economics
Insurance, Health, Reimbursement
/ economics
Inventions
/ economics
Longitudinal Studies
Young Adult
children
diabetes technology
reimbursement
type 1 diabetes
Journal
Pediatric diabetes
ISSN: 1399-5448
Titre abrégé: Pediatr Diabetes
Pays: Denmark
ID NLM: 100939345
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
26
07
2018
revised:
25
10
2018
accepted:
28
01
2019
pubmed:
19
2
2019
medline:
24
3
2020
entrez:
19
2
2019
Statut:
ppublish
Résumé
Frequent use of modern diabetes technologies increases the chance for optimal type 1 diabetes (T1D) control. Limited reimbursement influences the access of patients with T1D to these modalities and could worsen their prognosis. We aimed to describe the situation of reimbursement for insulins, glucometers, insulin pumps (CSII) and continuous glucose monitoring (CGM) for children with T1D in European countries participating in the SWEET Project and to compare data from EU countries with data from our previous study in 2009. The study was conducted between March 2017 and August 2017. First, we approached diabetes technology companies with a survey to map the reimbursement of insulins and diabetic devices. The data collected from these companies were then validated by members of the SWEET consortium. We collected data from 29 European countries, whereas all types of insulins are mostly fully covered, heterogeneity was observed regarding the reimbursement of strips for glucometers (from 90 strips/month to no limit). CSII is readily available in 20 of 29 countries. Seven countries reported significant quota issues or obstacles for CSII prescription, and two countries had no CSII reimbursement. CGM is at least partially reimbursed in 17 of 29 countries. The comparison with the 2009 study showed an increasing availability of CSII and CGM across the EU. Although innovative diabetes technology is available, a large proportion of children with T1D still do not benefit from it due to its limited reimbursement.
Sections du résumé
BACKGROUND
Frequent use of modern diabetes technologies increases the chance for optimal type 1 diabetes (T1D) control. Limited reimbursement influences the access of patients with T1D to these modalities and could worsen their prognosis. We aimed to describe the situation of reimbursement for insulins, glucometers, insulin pumps (CSII) and continuous glucose monitoring (CGM) for children with T1D in European countries participating in the SWEET Project and to compare data from EU countries with data from our previous study in 2009.
METHODS
The study was conducted between March 2017 and August 2017. First, we approached diabetes technology companies with a survey to map the reimbursement of insulins and diabetic devices. The data collected from these companies were then validated by members of the SWEET consortium.
RESULTS
We collected data from 29 European countries, whereas all types of insulins are mostly fully covered, heterogeneity was observed regarding the reimbursement of strips for glucometers (from 90 strips/month to no limit). CSII is readily available in 20 of 29 countries. Seven countries reported significant quota issues or obstacles for CSII prescription, and two countries had no CSII reimbursement. CGM is at least partially reimbursed in 17 of 29 countries. The comparison with the 2009 study showed an increasing availability of CSII and CGM across the EU.
CONCLUSIONS
Although innovative diabetes technology is available, a large proportion of children with T1D still do not benefit from it due to its limited reimbursement.
Substances chimiques
Blood Glucose
0
Hypoglycemic Agents
0
Insulin
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
434-443Investigateurs
N Papo
(N)
D Kownatka
(D)
Silvia Lion
(S)
P Gerhardsson
(P)
T Kalina
(T)
B Rami-Merhar
(B)
J Svensson
(J)
R Hanas
(R)
M Knip
(M)
M Witsch
(M)
R Verkauskiene
(R)
S Todorovic
(S)
P Toth-Heyn
(P)
M Ng
(M)
J Pelicand
(J)
K Podolakova
(K)
B Timar
(B)
K Casteels
(K)
R Cordona Hernandez
(R)
H Hoey
(H)
Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.